With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy

With a $35 million series D, EpicentRx hopes to take its immunotherapy through to an NDA and bring its oncolytic virus program to the clinic.

An undisclosed European investor was the sole investor in the round,

Read the full 368 word article

User Sign In